Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.49 |
| ▸ | JAK3 | P52333 | 12/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212684 | 0.85 | JAK2 (0.53) | JAK2JAK3PTK2 | |
| SCHEMBL19913 | 0.83 | JAK2 (0.50) | JAK2JAK3PTK2AURKAMEN1 | |
| SCHEMBL15212854 | 0.83 | JAK2 (0.67) | JAK2JAK3PTK2 | |
| SCHEMBL15210514 | 0.83 | JAK2 (0.53) | JAK2JAK3PTK2AURKAKDR | |
| SCHEMBL15210695 | 0.83 | JAK2 (0.58) | JAK2JAK3PTK2KDR | |
| SCHEMBL15221151 | 0.81 | JAK2 (0.46) | JAK2JAK3PTK2 | |
| SCHEMBL17035576 | 0.80 | JAK2 (0.45) | JAK2JAK3PTK2MEN1USP2 | |
| SCHEMBL16394411 | 0.80 | SYK (0.55) | JAK2JAK3MEN1USP2CYP1A2 | |
| SCHEMBL15210810 | 0.80 | JAK2 (0.58) | JAK2JAK3PTK2MEN1USP2 | |
| SCHEMBL21968 | 0.80 | JAK2 (0.54) | JAK2JAK3PTK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2015-01-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025058-A1 | 8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS | SYK, EIF2AK4, BTK | JAK2 29/4885JAK3 127/4885PTK2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.